Literature DB >> 25274062

Immunogenicity of necrotic cell death.

Jaba Gamrekelashvili1, Tim F Greten, Firouzeh Korangy.   

Abstract

The mode of tumor cell death has significant effects on anti-tumor immunity. Although, previously it was thought that cell death is an inert effect, different investigators have clearly shown that dying tumors can attract, activate and mature professional antigen presenting cells and dendritic cells. In addition, others and we have shown that the type of tumor cell death not only controls the presence or absence of specific tumor antigens, but also can result in immunological responses ranging from immunosuppression to anti-tumor immunity. More importantly, it is possible to enhance anti-tumor immunity both in vitro and in vivo by targeting specific molecular mechanisms such as oligopeptidases and the proteasome. These studies not only extend our knowledge on basic immunological questions and the induction of anti-tumor immunity, but also have implications for all types of cancer treatments, in which rapid tumor cell death is induced. This review is a comprehensive summary of cell death and particularly necrosis and the pivotal role it plays in anti-tumor immunity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25274062      PMCID: PMC6309818          DOI: 10.1007/s00018-014-1741-x

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  116 in total

1.  Discrete proteolytic intermediates in the MHC class I antigen processing pathway and MHC I-dependent peptide trimming in the ER.

Authors:  P Paz; N Brouwenstijn; R Perry; N Shastri
Journal:  Immunity       Date:  1999-08       Impact factor: 31.745

2.  The exception that reinforces the rule: crosspriming by cytosolic peptides that escape degradation.

Authors:  Avital Lev; Kazuyo Takeda; Damien Zanker; Jason C Maynard; Peniel Dimberu; Elizabeth Waffarn; James Gibbs; Nir Netzer; Michael F Princiotta; Len Neckers; Didier Picard; Christopher V Nicchitta; Weisan Chen; Yoram Reiter; Jack R Bennink; Jonathan W Yewdell
Journal:  Immunity       Date:  2008-06       Impact factor: 31.745

3.  The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation.

Authors:  A F Kisselev; T N Akopian; K M Woo; A L Goldberg
Journal:  J Biol Chem       Date:  1999-02-05       Impact factor: 5.157

4.  Calreticulin exposure dictates the immunogenicity of cancer cell death.

Authors:  Michel Obeid; Antoine Tesniere; François Ghiringhelli; Gian Maria Fimia; Lionel Apetoh; Jean-Luc Perfettini; Maria Castedo; Grégoire Mignot; Theoharis Panaretakis; Noelia Casares; Didier Métivier; Nathanael Larochette; Peter van Endert; Fabiola Ciccosanti; Mauro Piacentini; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Med       Date:  2006-12-24       Impact factor: 53.440

5.  Tripeptidyl peptidase II is the major peptidase needed to trim long antigenic precursors, but is not required for most MHC class I antigen presentation.

Authors:  Ian A York; Nidhi Bhutani; Sophia Zendzian; Alfred L Goldberg; Kenneth L Rock
Journal:  J Immunol       Date:  2006-08-01       Impact factor: 5.422

6.  Flexibility in substrate recognition by thimet oligopeptidase as revealed by denaturation studies.

Authors:  Jeffrey A Sigman; Tasneem H Patwa; Ana V Tablante; Calleen D Joseph; Marc J Glucksman; Adele J Wolfson
Journal:  Biochem J       Date:  2005-05-15       Impact factor: 3.857

7.  Analysis of intracellular substrates and products of thimet oligopeptidase in human embryonic kidney 293 cells.

Authors:  Denise A Berti; Cain Morano; Lilian C Russo; Leandro M Castro; Fernanda M Cunha; Xin Zhang; Juan Sironi; Clécio F Klitzke; Emer S Ferro; Lloyd D Fricker
Journal:  J Biol Chem       Date:  2009-03-12       Impact factor: 5.157

8.  Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Authors:  Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Michel Obeid; Carla Ortiz; Alfredo Criollo; Grégoire Mignot; M Chiara Maiuri; Evelyn Ullrich; Patrick Saulnier; Huan Yang; Sebastian Amigorena; Bernard Ryffel; Franck J Barrat; Paul Saftig; Francis Levi; Rosette Lidereau; Catherine Nogues; Jean-Paul Mira; Agnès Chompret; Virginie Joulin; Françoise Clavel-Chapelon; Jean Bourhis; Fabrice André; Suzette Delaloge; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2007-08-19       Impact factor: 53.440

Review 9.  Autophagy, immunity, and microbial adaptations.

Authors:  Vojo Deretic; Beth Levine
Journal:  Cell Host Microbe       Date:  2009-06-18       Impact factor: 21.023

10.  Phosphatidylserine receptor is required for clearance of apoptotic cells.

Authors:  Ming O Li; Matthew R Sarkisian; Wajahat Z Mehal; Pasko Rakic; Richard A Flavell
Journal:  Science       Date:  2003-11-28       Impact factor: 47.728

View more
  12 in total

Review 1.  Combined locoregional-immunotherapy for liver cancer.

Authors:  Tim F Greten; Michal Mauda-Havakuk; Bernd Heinrich; Firouzeh Korangy; Bradford J Wood
Journal:  J Hepatol       Date:  2019-02-07       Impact factor: 25.083

Review 2.  Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer.

Authors:  Matthew R Woeste; Anne E Geller; Robert C G Martin; Hiram C Polk
Journal:  Ann Surg Oncol       Date:  2021-01-03       Impact factor: 5.344

Review 3.  Boosting Tumor-Specific Immunity Using PDT.

Authors:  Nicole Maeding; Thomas Verwanger; Barbara Krammer
Journal:  Cancers (Basel)       Date:  2016-10-06       Impact factor: 6.639

Review 4.  Radiation, inflammation and the immune response in cancer.

Authors:  Kelly J McKelvey; Amanda L Hudson; Michael Back; Tom Eade; Connie I Diakos
Journal:  Mamm Genome       Date:  2018-09-03       Impact factor: 2.957

Review 5.  Contribution of Angiogenesis to Inflammation and Cancer.

Authors:  Dolores Aguilar-Cazares; Rodolfo Chavez-Dominguez; Angeles Carlos-Reyes; César Lopez-Camarillo; Olga N Hernadez de la Cruz; Jose S Lopez-Gonzalez
Journal:  Front Oncol       Date:  2019-12-12       Impact factor: 6.244

6.  Enhanced T Cell Responses Induced by a Necrotic Dendritic Cell Vaccine, Expressing HCV NS3.

Authors:  Zelalem A Mekonnen; Makutiro G Masavuli; Wenbo Yu; Jason Gummow; Dawn M Whelan; Zahraa Al-Delfi; Joseph Torresi; Eric J Gowans; Branka Grubor-Bauk
Journal:  Front Microbiol       Date:  2020-11-24       Impact factor: 5.640

Review 7.  Cancer vaccines as promising immuno-therapeutics: platforms and current progress.

Authors:  Jian Liu; Minyang Fu; Manni Wang; Dandan Wan; Yuquan Wei; Xiawei Wei
Journal:  J Hematol Oncol       Date:  2022-03-18       Impact factor: 17.388

8.  Necroptosis-driving genes RIPK1, RIPK3 and MLKL-p are associated with intratumoral CD3+ and CD8+ T cell density and predict prognosis in hepatocellular carcinoma.

Authors:  Lorenzo Nicolè; Tiziana Sanavia; Rocco Cappellesso; Valeria Maffeis; Jun Akiba; Akihiko Kawahara; Yoshiki Naito; Claudia Maria Radu; Paolo Simioni; Davide Serafin; Giuliana Cortese; Maria Guido; Giacomo Zanus; Hirohisa Yano; Ambrogio Fassina
Journal:  J Immunother Cancer       Date:  2022-03       Impact factor: 13.751

9.  Interdisciplinary Study of the Effects of Dipeptidyl-Peptidase III Cancer Mutations on the KEAP1-NRF2 Signaling Pathway.

Authors:  Sara Matić; Ana Tomašić Paić; Sandra Sobočanec; Marija Pinterić; Goran Pipalović; Monika Martinčić; Mihaela Matovina; Sanja Tomić
Journal:  Int J Mol Sci       Date:  2022-02-11       Impact factor: 5.923

10.  Cryo-thermal therapy elicits potent anti-tumor immunity by inducing extracellular Hsp70-dependent MDSC differentiation.

Authors:  Jun Zhu; Yan Zhang; Aili Zhang; Kun He; Ping Liu; Lisa X Xu
Journal:  Sci Rep       Date:  2016-06-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.